A New Treatment for Dialysis-Related Amyloidosis with β 2-Microglobulin Adsorbent Column
A New Treatment for Dialysis-Related Amyloidosis with β 2-Microglobulin Adsorbent Column
复制标题
β2-微球蛋白吸附柱治疗透析相关淀粉样变性的新方法
DOI：
--
复制
发表时间：
1993
影响因子：
1.7
通讯作者：
F. Kobayashi
中科院分区：
文献类型：
--
作者：
R. Nakazawa;N. Azuma;M. Suzuki;M. Nakatani;T. Nankou;S. Furuyoshi;A. Yasuda;S. Takata;N. Tani;F. Kobayashi
透析相关性淀粉样变性的特征是血浆中存在β-2-微球蛋白(β-2-m)。为了去除循环血中的β2-m，研制了用于直接血液灌流的β2-m选择性吸附剂。DHP柱(BM-01)，包含350毫升的吸附剂，进行了临床试验。柱与PAN(AN69)膜透析器串联，每周使用3次，分别为1周(11例)、4周(5例)、6个月(1例)和12个月(2例)。β2-m下降(%)16例(1~4周)，>65；3例(>6个月)，分别为76.5±4.9、73.5±5.7、72.2±6.2。在每一疗程结束时，β-2-m血浆水平均低于10 mg/L，最低为3.4 mg/L。β2-m的最大清除量分别为172.5±22.3、257.0±75.6、157.6±32.2和429.8 mg/次。3例患者中有2例对关节症状和眼底有良好的疗效。结论：选择性吸附疗法可延缓DRA的进展，值得推广应用。
Dialysis-related amyloidosis (DRA) is characterized by the presence of β 2-microglobulin (β 2-m) in the plasma. In order to eliminate β 2-m from the circulating blood, the β 2-m selective adsorbent for direct hemoperfusion (DHP) was developed. A DHP column (BM-01), containing 350 ml of the adsorbent, was subjected to clinical trials. The column was connected with a PAN (AN69) membrane dialyzer in series and used 3 times a week for 1 week (11 patients), 4 weeks (5 patients), 6 months (1 patient) and 12 months (2 patients). The percent reduction (%) of β 2-m was for 16 patients (for 1 or 4 weeks), more than 65, and for 3 patients (for more than 6 months), 76.5 ± 4.9, 73.5 ± 5.7, 72.2 ± 6.2. At the end of each session, β 2-m plasma levels were found to be below 10 mg/L, with 3.4 mg/L being the lowest. The total amounts of β 2-m removed were 172.5 ± 22.3, 257.0 ± 75.6, 157.6 ± 32.2 and 429.8 mg/session at max. Two out of these three patients had a favorable effect on joint symptoms and ocular fundus. It can be concluded that this selective adsorption therapy may delay the progression of DRA, and is worth considering for wide application.
影响因子：
56.9
作者：
BRINCKERHOFF, CE;MITCHELL, TI;BENSON, MD
通讯作者：
BENSON, MD